STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #815 by analyst upside · 2026-06-27
PRME
Prime Medicine, Inc.
Healthcare · Market Cap $620M · P/E 0x
ANALYST PRICE TARGET
+101.7%
implied upside to consensus target
Current Price $3.43
Consensus Target $6.92
Bull Target $11.0
Bear Target $4.25
Analysts Covering 9
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
6
Hold
3
Sell
0
52-Week Low $2.28
52-Week High $6.94
YTD Return -2.8%
FUNDAMENTALS
Market Cap $620M
P/E Ratio (TTM) N/A
Forward P/E -3.9x
EPS (TTM) $-1.33
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $4M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.28
52-Week High $6.94
Current Price $3.43
Bear Target $4.25
Bull Target $11.0
● Now $3.43 ● Target $6.92
TRADING DATA
Avg Volume 2.5M
YTD Return -2.8%
Analyst Count 9
Consensus Buy
Upside to Target +101.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Prime Medicine, Inc. (PRME) is currently trading at $3.43 with a Wall Street consensus price target of $6.92, implying potential upside of 101.7% over the next 12 months. 9 analysts currently cover PRME, with a consensus rating of Buy — 70% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $4.25.

PRME operates in the Healthcare sector with a market capitalisation of $620M. The stock is down 2.8% year-to-date and is currently trading near the lower end of its 52-week range of $2.28 – $6.94.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRME, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer ● Initiated
Outperform 2026-03-12 14% win rate (7 calls)
LifeSci Capital ● Initiated
Outperform 2025-12-23 Building track record
Citigroup — Reiterated
Neutral → Neutral 2025-11-11 Building track record
Chardan Capital — Reiterated
Buy → Buy 2025-11-10 33% win rate (6 calls)
Citigroup — Reiterated
Neutral → Neutral 2025-08-12 Building track record
Chardan Capital — Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
Citigroup ↓ Downgrade
Buy → Neutral 2025-05-27 Building track record
JMP Securities — Reiterated
Market Outperform → Market Outperform 2025-05-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →